Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

April 24, 2025

New York Stock Exchange US Health Care Pharmaceuticals earnings 62 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Appreciate that, Dustin, and hello everyone on this morning's call. We're glad to have you with us for Merck & Co., Inc.'s First Quarter 2025 Conference Call, broadcasting from Rahway, New Jersey, U.S.A. On the line today: Rob Davis, who serves as our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Research Labs. A quick note before we get started — items such as acquisition-related charges, restructuring costs, and certain other things are part of our GAAP results, and all of those have been left out of our non-GAAP results. Our press release contains a reconciliation you can review. Before we go further, I want to note that certain things we say today could fall under the forward-looking statement category as defined by the safe harbor provision of The U.S. Private Securities Litigation Reform Act of 1995. What we express reflects what our company's management currently believes, and it comes with substantial risks and uncertainties. If the assumptions underneath turn out to be wrong, or if uncertainties come to pass, then actual results might diverge materially from what those forward-looking statements set forth. Within our SEC filings — Item 1A and the 2024 10-Ks included — you'll find specific risk factors and cautionary statements describing circumstances that could lead the company's actual results to differ materially from anything projected in the forward-looking statements we've made this morning. Merck & Co., Inc., based in Rahway, New Jersey, USA, makes no promise to revise any forward-looking statements publicly. A slide deck will go along with what our speakers have ready to say on today's call. You can find those slides, plus the earnings release, today's prepared remarks, and our SEC filings, posted in the Investor Relations area of our corporate site. Having said that, I'll hand things over to Rob.

Rob Davis

executive
#2

Thanks, Peter. Morning, everyone, and I appreciate you being on the call today. We got off to a solid start this year, with our newer marketed medicines and vaccines contributing more and more, plus steady pipeline progress; we're pushing ahead with determination and speed to capture everything our near-term opportunities can deliver and to move quickly on the following wave of innovation, which will make a real difference for the patients we serve and generate value down the road for all stakeholders. Given how dynamic things are globally, we keep engaging regulators and policymakers worldwide to address some of the largest health issues and to secure access for patients and customers to our medicines and vaccines that save and improve lives. During the past several years, we've been reshaping how we approach our supply chain so we can strike a better balance in our manufacturing footprint — something that fits nicely with the new administration's push to rebuild US manufacturing; you can see this in what we've done starting when the Tax Cut and Jobs Act passed and speeding up after the pandemic. Notably, we've put $12 billion into US manufacturing since 2018, and we've pledged another $9 billion plus toward projects running through 2028. Because of these investments, a greater share of our products for American patients are being made here in the US, and we're seeing more export opportunities too. Now to our Q1 results: performance came in as we expected, with revenue reaching $15.5 billion, driven by strength in oncology, animal health, and growing meaningful contributions from the ongoing strong launches of WINREAVER and Cafaxib. Looking ahead, we stay confident about our outlook for better growth during the second half of the year. Given where things stand right now, we're keeping our full-year revenue and EPS guidance unchanged, excluding business development charges, which Caroline will cover in greater detail. Gains from better foreign exchange are partly offset by roughly $200 million in anticipated costs tied to tariffs put in place so far, mostly between the US and China and to a smaller extent Canada and Mexico. Regarding possible further US tariffs, particularly on pharmaceuticals, our worldwide supply chain and existing inventory leave us well positioned to handle any near-term effects. And our continuing work to shift more manufacturing into the US for US supply, including for most of our forthcoming new products, will help us manage across the medium and long term. Reflecting on how 2025 has begun, I take pride in how our research keeps moving forward. We recently shared key phase three data for wind repair in additional patient groups, reinforcing the strong promise this product holds for improving the lives of more individuals dealing with pulmonary arterial hypertension. Beyond that, our HIV pipeline is coming into clearer view now, with data readouts from two phase three trials involving zolotrovir-based regimens. Fresh clinical studies getting underway, along with regulatory filings in oncology, only strengthen our conviction that we're positioned strongly to lead over the long haul, with the prospect of aiding an even greater number of people battling cancer. Biopharmaceutical breakthroughs of the magnitude we're pursuing aren't gauged across quarters — they're gauged across years. On that front, the momentum we're witnessing is persuasive. From 2021 onward, we've expanded our late-phase pipeline to almost three times its former size, achieved both by moving forward compounds we discovered in-house and by closing many significant business development deals spanning several therapeutic areas marked by substantial unmet need, such as oncology, cardiometabolic, ophthalmology, and immunology. Taken together, these endeavors have produced a broader late-phase pipeline made up of programs whose combined potential commercial opportunity exceeds $50 billion by the mid-2030s. Wind rebar and CapVaxin are the first launches to emerge from this strong pipeline of 20 promising prospective new growth drivers that we anticipate reaching the market across the coming few years, nearly every one of which carries blockbuster potential. Going forward, we have an abundant lineup of data readouts, presentations, filings, and further approvals. Among the world's most scientifically sophisticated modalities are those in our pipeline, and Dean, together with our research colleagues, is moving ahead several molecules possessing foundational multi-indication promise in areas where unmet need is significant; beyond that, we've broadened and lengthened our dedication to early research and development. In the coming few years, anticipate that a great many of these programs will move into Phase two and become visible to you. Owing to the remarkable work of our committed team and the solid progress we're making, we're confident we're positioned well to steer successfully through the KEYTRUDA LOE period. Even so, our work isn't done. Business development grounded in science and value stays a leading priority. We keep evaluating opportunities promptly, focused on generating near- and long-term growth along with value creation; to sum up, our numbers demonstrate sustained appetite for breakthrough treatments and innovative solutions capable of tackling worldwide health challenges. Drawing on our scientific leadership, we're delivering the coming wave of innovation able to save and better lives globally. The commercial results we post today keep fueling progress across our pipeline and, in turn, build long-term value for patients, customers, and shareholders; we stay assured about our strategic course, our dedication to research and development as the wellspring of sustainable value creation, and our lasting pledge to make a positive difference for patients; with that, I'll hand the call to Caroline.

Caroline Litchfield

executive
#3

Thank you, Rob. Good morning. As Rob pointed out, our performance in the first quarter matched what we had anticipated. Our business fundamentals stay sound, supported by strong worldwide appetite for our innovative portfolio; we have confidence in our capacity to fulfill today's commitments while making strategic investments that pave the way for tomorrow's innovations, drawing on cutting-edge science to save and improve lives globally. Now moving to our results for the first quarter, total company revenues reached $15.5 billion, which is a decline of 2%. Or a rise of 1% when you exclude the foreign exchange impact. As anticipated, results took a hit from lower Gardasil sales in China, roughly $1.1 billion, which cut growth excluding foreign exchange by seven percentage points. Setting aside those sales and the foreign exchange effect, worldwide growth came in at 8%, mainly powered by new products, WinRevair and Capfaxiv, plus momentum in oncology and animal health. The revenue remarks that follow will use an ex-exchange basis. Within oncology, Keytruda sales rose 6%, reaching $7.2 billion. Global growth came from greater uptake in earlier-stage cancers, along with strong demand for metastatic indications. In the earlier stage setting, growth stemmed from higher utilization in triple-negative breast cancer, renal cell carcinoma, and non-small cell lung cancer. For metastatic disease, we observed greater use of KEYTRUDA alongside PADCEF in first-line locally advanced urothelial cancer. Plus Keytruda combined with chemotherapy in first-line endometrial cancer; within the US, as we communicated before, growth faced a negative hit of about $250 million because of the timing of wholesaler purchases. Our wide oncology portfolio delivered robust growth led by Wellyreg, with sales climbing 63% to $137 million thanks to greater use in certain patients with previously treated advanced renal cell carcinoma in the US. Welireg has become the market leader for treating patients with advanced renal cell carcinoma after prior therapies; in vaccines, GARDASIL sales totaled $1.3 billion, down 40%, pulled lower by China where channel inventories remain elevated and demand stays soft. Everywhere else, growth was 16%; in the US, sales gained from price and demand. Beyond the US and China, growth came from higher overall demand, including the catch-up cohort in Japan; in pneumococcal, Cafaxib sales hit $107 million, mainly on demand from the retail pharmacy segment; we've made excellent progress in these early launch stages, and are well-positioned to help protect adults from invasive pneumococcal disease. Vaxnuvan sales rose 7% as growth from international market launches was partly offset by competitive pressures in the US. In cardiovascular, the strong momentum of the ongoing WinRefer launch continues, with global sales of $280 million. The launch keeps performing in line with our high expectation and we remain excited about the significant benefit WinRevair is providing for patients. In the US, more than fourteen hundred new patients received prescriptions during the quarter. We keep observing a consistent rise in the share of new prescriptions written for patients whose background PAH treatments don't involve a prostacyclin. Beyond the US, we keep moving forward with launches and reimbursement. All in all, we're quite happy with how WinRev is being taken up, and we're eager to make a positive difference for more people living with pulmonary arterial hypertension. The added strength of data from the clinical development program — which Dean will discuss shortly — gives physicians and patients even more confidence. It also reinforces our conviction about WinRev's considerable potential. Our animal health segment turned in yet another quarter of strong growth, with sales up 10%. Livestock gains mirror stronger demand across every species, plus the benefit from ruminant sales timing and revenue from the Aqua portfolio we bought from Elanco. Companion animal sales growth mirrors price. I'll now take you through the rest of our P&L, and my remarks will be on a non-GAAP basis. Gross margin came in at 82.2%, up one percentage point, driven by favorable product mix. Operating expenses fell to $6.1 billion. We had no significant business development expenses this quarter, versus the $656 million charge taken a year ago. Leaving out that charge, operating expenses rose 6%, reflecting disciplined investments backing our strong early and late-phase pipeline and key growth drivers. Other expense totaled $75 million. Our tax rate of 14.2% got a boost from certain discrete items. All together, earnings per share were $2.22. Now let's turn to our 2025 non-GAAP guidance. As Rob mentioned, we're keeping our full-year revenue guidance at between $64.1 billion and $65.6 billion. That range equals growth of 1% to 3%, excluding a roughly 1% negative foreign exchange impact at mid-April rates. Our gross margin assumption is now about 82%; that figure includes roughly $200 million in costs tied to tariffs put in place so far. Operating expenses are now projected at between $25.6 billion and $26.6 billion. This range now incorporates a $200 million payment tied to the license agreement with Hungry Pharma, which should close in the second quarter. It also incorporates the $300 million tech transfer payment tied to Lenovo, which stays in our guidance but hasn't happened yet. As a reminder, our guidance doesn't assume any additional significant potential business development transactions. Other expense should land between $300 million and $400 million. We assume a full-year tax rate of between 15.5% and 16.5%; we assume roughly 2.51 billion shares outstanding. All together, we expect EPS of $8.82 to $8.97. This range incorporates a negative foreign exchange impact of more than $0.20 at mid-April rates. Recall that our earlier guidance range was $8.88 to $9.03. Were it not for the one-time charge of $200 million tied to Hongray, or $0.06 per share, our guidance range is unchanged. As you think about your models, here are a few items to keep in mind. After Japan’s successful HPV catch-up immunization effort, we anticipate that uptake will ease, since most future sales will come from the primary age group. Consequently, although worldwide Gardasil growth outside China remains robust, it is expected to decelerate moving ahead. With Keytruda, wholesaler buying patterns in the US cut sales by about $250 million during Q1, and should add roughly an equivalent lift to Q3 sales. Keep in mind that we cut list prices for the US Januvia product family at the start of 2025. Those lower list prices brought down the rebate sum our company owes Medicaid. Because of that, we anticipate greater net sales for these items during 2025. US sales of the Januvia family in Q1 were also helped by over $100 million from favorable one-time true-ups. Now on capital allocation. Our approach is still the same; we will keep putting priority on investing in our business to generate near- and long-term growth and returns for shareholders. Our company is quickly advancing toward a future featuring a more diversified set of growth drivers. As we keep evaluating our business, we are likely to pursue moves aimed at maximizing these opportunities’ potential through disciplined investment while reshaping our business to generate ongoing productivity throughout the company; we plan to share more about such efforts later in the year; we stay dedicated to our dividend, aiming to raise it over time. Business development is still a key priority. We keep actively reviewing chances to carry out further science-driven, value-creating transactions. We raised share repurchases during the quarter to about $1.2 billion, matching the amount for all of 2024. Given our strong balance sheet, we expect the repurchase pace to stay at this level. Our highest priority, though, is still to invest completely behind our growth drivers and pipeline, plus business development. In closing, we are confident about our business outlook, powered by our strong portfolio and outstanding pipeline. With innovation investment and our continued emphasis on execution, we are well placed to deliver value to patients, customers, and shareholders today and far into the future. With that, I’d like to hand the call over to Dean.

Dean Li

executive
#4

Appreciate that, Caroline. Good morning, all. We maintained our forward motion through the first quarter, continuing a steady string of positive clinical and regulatory milestones. During today's comments, I'll walk through what's new with our cardiometabolic, HIV, and vaccine efforts, and then close with oncology. Starting with cardiometabolic disease: winrevir — the only approved active-in-signaling inhibitor, and the first one, for pulmonary arterial hypertension treatment — has continued to deliver clear-cut evidence of benefit across a broad spectrum of PAH patients since it first won approval just over a year ago. Last month, at the American College of Cardiology's ACC 25 conference, detailed results from the phase 3 ZENITH trial, which evaluated high-risk PAH patients, were shared. Those findings demonstrated a substantial 76% drop in risk for the composite of death from any cause, lung transplantation, and PAH hospitalization, with the Kaplan Meier curve showing separation both early and sustained, appearing as soon as four to five weeks following initiation of windrow bearer. Simultaneously, the results appeared in the New England Journal of Medicine. Zenith stands as the initial positive PAH trial whose primary endpoint was made up wholly of major outcome measures, and the first halted ahead of schedule because of overwhelming efficacy. This meaningful decrease in the risk of major morbidity and mortality events strengthens WinRevir's efficacy. Safety findings from Zenith were broadly in line with what earlier studies showed. As a reminder, because of the zenith study's early stoppage and a review of all data from the winrevir clinical program gathered so far, the external steering committee concluded that the Phase III Hyperion study no longer had clinical equipoise and ought to be stopped early as well. Every participant has now been offered the choice to receive winravir. We expect to share Hyperion study data sometime later this year. The clinical benefit along with the statistically significant improvement seen across a variety of patients who received winravir in the STEALAR and ZENITH studies offer solid evidence that it could change practice and shift the trajectory for those living with this devastating disease. Our clinical efforts also take in the ongoing Suteria long-term extension trial, along with the phase two light ray study, which is moving forward to support creating an auto-injector choice for patients. In addition, the phase two CADANCE trial, looking at the opportunity in pulmonary hypertension caused by left heart disease — a specific subgroup within WHO group two — has completed enrollment and is still on track to finish later this year. We continue to build out our pipeline of candidates targeting cardiometabolic disease; in March, we announced an exclusive licensing deal with Hungry Pharma covering HRS five three four six, an investigational oral small molecule lipoprotein a, or LP little a, formation inhibitor. Elevated lipoprotein(a) concentrations in the bloodstream are a genetic contributor to atherosclerotic cardiovascular disease risk, and no therapy has won approval to address it so far. A phase two study of HRS five three four six has just been launched in China by Hong Rui, and we are assembling a robust global clinical development effort that expands and complements our broader cardiometabolic portfolio. In addition to vaccines, we continue to secure regulatory authorizations across the globe for Cavaxib. In the latest development, the European Commission has approved active immunization intended to prevent invasive disease and pneumonia caused by streptococcus pneumoniae in adults. The rationale behind that choice comes from safety and immunogenicity findings generated across multiple pivotal trials in the program, and it represents the fourth green light, after prior clearances in the US, Canada, and Australia. China's National Medical Products Administration has just granted GARDASIL 9 approval to help guard against certain associated cancers and diseases among males aged 16 to 26, making it the initial nine-valent HPV vaccine authorized in China for certain males as well as females. Turning now to HIV. Back in March, at the Conference on Retroviruses and Opportunistic Infections, we shared detailed findings from two key phase three studies. These studies looked at adults whose HIV-1 was already virologically suppressed and who then switched to an investigational once-daily oral fixed-dose combo of doravirine plus ezlotrovir — ezlotrovir being an investigational nucleoside reverse transcriptase translocation inhibitor. By week forty-eight in both studies, the doravirine and islacivir combination hit the primary efficacy success criteria, showing non-inferiority against comparator antiretroviral therapies, and also met the primary safety goals. This doravirine and enzlotrovir pairing is the first complete two-drug regimen that doesn't include an integrase strand transfer inhibitor to show efficacy and safety comparable to Biktarvy, a three-drug INSTI-based regimen, in a phase three trial. We're planning to submit marketing authorization requests to regulators before the midpoint of this year. Those results, along with further studies testing longer-acting treatment and PrEP regimens, highlight how dedicated we remain to developing novel choices that meet the shifting requirements of individuals both at risk for HIV and those already living with the virus. Now, moving to oncology. At the European Lung Cancer Congress last month, we shared comprehensive results from a key Phase III study that looked at giving the investigational subcutaneous fixed-dose combo of pembrolizumab and ver hyaluronidase alpha every six weeks alongside chemo, compared with intravenous Keytruda plus chemo. That trial achieved both of its primary goals, showing pharmacokinetics for subcutaneous pembrolizumab that were non-inferior to intravenous Keytruda. Efficacy and safety endpoints came back with consistent findings no matter which treatment arm was involved. When subcutaneous pembrolizumab was given on a six-week schedule, administration took a median of roughly two minutes. That's a substantial decrease from how long it takes to deliver Keytruda through an IV infusion. Also worth noting: next week at the American Association Cancer Research meeting, findings from a separate trial looking at a three-week dosing schedule are going to be shared. A PDUFA date of September 23 has been established by the FDA, and the European Medicines Agency is in the process of reviewing the application. What we're pursuing approval for is a choice between six-week and three-week dosing. Subcutaneous pembrolizumab, should it gain approval, would deliver a valuable choice to patients and health care systems alike — particularly for people being treated in earlier stage settings. In terms of approved uses, Keytruda still stands alone in its breadth, and it makes a real difference for patients. For those newly diagnosed with stage III or IVA resectable locally advanced head and neck squamous cell carcinoma, the FDA granted priority review to Keytruda as part of a perioperative regimen, a ruling based on the keynote six eighty-nine study. The PDUFA date falls on June 23. Just to remind everyone, when it comes to individuals who have undergone resection for locally advanced head and neck squamous cell carcinoma, nothing like this study has been conducted for two decades. On top of that, it stands as the initial phase three study to show, with statistical significance, that giving treatment both before and after surgery delivers an event-free survival advantage for patients who are newly diagnosed in this setting. Stepping in sooner may be able to enhance outcomes and reduce how heavily this disease weighs on these patients. We intend to file the findings with regulatory authorities, and if an approval is granted, that would make this the tenth indication for a regimen containing KEYTRUDA aimed at earlier-stage cancer. Next week, at the American Association for Cancer Research meeting, the detailed findings are set to be shared. There, it could matter a lot to take a close look at the Kaplan Meier plot — specifically how the curves separate — as an indicator that event-free survival is benefiting patients. From the LightSPARK four and LightSPARK five trials, we obtained the first conditional approval from the European Commission for Wellerig. This is for treating adults who have von Hippel Lindau disease and need therapy for associated localized renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors. It also covers advanced clear cell RCC that had progressed after two or more prior lines of therapy, which included a PD-one or a PD L1 inhibitor along with at least two vascular endothelial growth factor targeted therapies. Save the date: the evening of Monday, June 2, we're hosting an investor event during the 2025 ASCO Annual Meeting in Chicago, and there we'll share where our pipeline stands along with the newest developments in our oncology strategy. To wrap up, there are several milestones coming up in the near term that we're watching for during this year. In oncology, that includes PDUFA dates on the horizon for keynote six eighty-nine, plus an earlier stage head and neck squamous cell carcinoma indication in June, and subcutaneous pembrolizumab in September. Turning to RSV, there's an upcoming PDUFA for clozroblimab in June. Within the cardiometabolic area, we expect results from three phase three registration enabling studies that are evaluating enlicitide, our oral PCSK9 inhibitor candidate, for treating hypercholesterolemia. Also ahead is the fall primary completion date scheduled for the phase two CADANCE study, which is evaluating winravir in pulmonary hypertension due to left heart disease, along with the final readout from the phase three HYPERIAN study. Finally, regarding HIV, we are submitting an application for the doravirin and enzotrovir combination, along with data from the Phase IIa study of MK-eight thousand five hundred twenty-seven, an innovative NRTTI candidate that could serve as a significant once-monthly oral choice for pre-exposure prophylaxis. To wrap up, we keep moving our pipeline forward and carrying out our strategy quickly and carefully, and I'm eager to share more news about our advancements; at this point, I'll hand the call over to Peter.

Peter Dannenbaum

executive
#5

Appreciate that, Dean. Dustin, let's open it up for Q and A; we'd ask that the analysts keep it to a single question, if you would. Everyone, if you'd like to pose a question, kindly hit 1 on your phone's keypad. Pressing 2 lets you pull your question back whenever you like. Should you be on a speakerphone, lift the handset first, then press the numbers. To repeat, if you have a question, you can press 1. Please hold for a moment while we take our first question. That first question comes from Geoff Meacham of Citibank. Please go ahead. Your line is open.

Geoff Meacham

analyst
#6

I suppose I'll start things off by asking about tariffs. Rob, I get that discussing details isn't easy. Still, at a broad level, could you describe what Merck is doing to offset them — perhaps through a fresh CapEx cycle, adjustments to supply chain components, or maybe lifting US prices? Thanks a lot.

Rob Davis

executive
#7

Yes. Geoff, thanks for bringing that up. As you're aware, Caroline addressed the tariffs we've accounted for. Within our results announced thus far, that's $200 million. To clarify, this pertains to previously disclosed tariffs, mostly involving China and the US, and to a smaller degree, Canada and Mexico. What you're likely getting at is the chance of additional sector-specific tariffs down the road and our preparations. On that front, we've stayed quite focused, and I attempted to emphasize this in the script. Actually, we began altering and rebalancing how we approach our supply chain all the way back, starting with the Tax Cut and Jobs Act. That's when we began shifting toward a setup where the US serves the US, Europe serves Europe, and Asia serves Asia. We've been working through that; it formed a major piece of our announcement that we've invested $12 billion from then until now. Beyond that, we anticipate investing another 9 plus billion dollars — and honestly, I believe that figure will rise. Looking ahead. So we were already reworking our supply chain. What we've done specifically for the near term is, I believe, manage our M well. When you consider 2025, our inventory puts us in a strong spot to offset whatever might arise soon; then over the medium to long term, we've begun pinpointing places where we can either relocate our own production — meaning shift what existing plants prioritize — or add external manufacturing in certain instances to fill gaps. And lastly, to establish internal manufacturing over the long term. That way we'll have it built into our foundation moving ahead. So honestly, from my view, near term, we're sitting fine. Medium and long term, we're making moves to set ourselves up; that truly represents our core efforts; we aren't relying on and don't really view pricing as the mechanism for tariffs. Given there are always constraints on what's possible there; so for us, it comes down more to how we refine our supply chain; though, once more, much of what we're doing right now, honestly, was already in motion. So in many respects, we're in step with what the administration aims to accomplish and believe we're positioned to carry that out fairly effectively. Great. Thanks, Geoff. Next question, please, Dustin.

Tim Anderson

analyst
#8

Moving on, our following question comes from Tim Anderson with Bank of America. Rob, I'd like to raise the topic of long-term guidance. This came up when I asked three months ago, and here I am asking once more. There's a great deal of worry regarding KEYTRUDA as it heads into the IRA, with a patent cliff arriving at the close of twenty-eight. From where I sit, absent any clarity from you folks about what that implies, looking out to '28, my concern is that this will keep weighing on the share price, which currently changes hands at a single-digit p multiple — a place Merck stock has sat only one other time across the past twenty-five years, that being an o nine after you buy sharing plow. Back when I posed this three months ago, your response suggested you might provide it at some stage. With the stock still tending to slide downward, I'm curious where your thinking stands on that. Thank you.

Rob Davis

executive
#9

Yes. Tim, I appreciate the question. At the JPMorgan conference, our aim — and I believe this is clear to everyone — was to really bring into focus how confident we are about our long term, doing so by zeroing in on how strong the pipeline is. In our script I pointed out that over 20 new products are on our radar to arrive across the coming years. Virtually every one of them could become a blockbuster. When you consider all of them together and project ahead, they genuinely account for the majority of that $50 billion plus opportunity we anticipate in the early to mid-twenty thirties. So I think that offers everyone a picture of what we're up to — though whether we take it further and hand out specific line by line guidance, at this moment no plan exists on our end to do so, yet we keep assessing it. And we will, you know, get a read on how the bulk of investors feel about it. Honestly, plenty of people we've heard from don't share your view. Right. Tim. Dustin, let's take the next question, please.

Luisa Hector

analyst
#10

Our next question comes from Luisa Hector at Berenberg. Please go ahead, your line is open. Hi there. I appreciate you taking my question. Could you maybe share some thoughts on the shifts we're observing at the FDA and HHS, especially when it comes to vaccines, and what you see ahead? Thanks.

Dean Li

executive
#11

Yeah, this is Dean. Appreciate the question. When it comes specifically to the FDA, what I'd say is that we have programs with upcoming PDUFA dates that we've listed, such as clasorbimab, subcu, Keynote six eighty-nine, and everything we've heard in our communications points to those staying on track. In fact, there's quite active dialogue regarding FDM programs with near-term filings, which includes enlista and also, for instance, when we're bearer as we speak about possible label changes. What we can't address is what the many personnel transitions at the FDA will mean over the mid to long term. That's simply something we'll have to watch and see, and stay very vigilant about. However, when it comes to the imminent PDUFA date and the active dialogues we've had on programs we've been discussing with them over the last year year and a half, no shift in timelines has appeared.

Peter Dannenbaum

executive
#12

Great. Thanks, Luisa. Next question, please, Dustin.

Vamil Divan

analyst
#13

Our next question comes from Vamil Divan with Guggenheim Securities. Please proceed. Your line is open. So perhaps, once more, just some bigger-picture or macro-type items here. There are two, quite clearly. First, you said that business development ranks as a top priority. I'd like to know whether you might just offer some thoughts on what the landscape for business development looks like right now, given all the volatility in the macro backdrop and the tariff-related unknowns. And so forth. Just, you know, mercy. Would you be open to doing, you know, a larger kind of deal, or perhaps a bolt-on of a more meaningful size? And on the seller side as well, is there, you know, a readiness to sell right now? So any thoughts on that would be welcome. The second subject that keeps arising now concerns the possibility of some form of international reference pricing. Under which US prices might become linked in some manner to prices outside the US. Clearly, there are many unknowns there as well, but if you could share your view on that, or any insights you may have about that possibly coming to pass. Thank you.

Rob Davis

executive
#14

Yeah. No. Thank you, Vamil, for those questions. Regarding the first one, the macro environment and what it means from a business development standpoint, perhaps just for context, to be clear, our emphasis on business development has not changed. Our wish, and our conviction, that we must keep finding new opportunities grounded in science so we can keep building the pipeline. Has not changed, and so our strategy carries on. When we consider the environment, I mean, plainly the what's taking place does make it more complex. To get things completed, because of the uncertainty that everyone is grappling with. And we are doing all we can to ensure we reflect that when we think about value and what we are prepared to pay under those conditions. But it isn't preventing us from being aggressive and wanting to push ahead and complete deals. When it comes to the sellers, I would say that, you know, we keep seeing, at least in the conversations we've had, something of a disconnect between what the reality of the market is that the sellers confront and what their expectation for value happens to be. I don't believe they have fully yet aligned themselves with the realities of where we stand today. And so we keep pushing ahead, but that is sort of the environment we seek; and but I am confident that you are gonna see us get some things done as we move forward, because we've got items in the queue that we're looking for. Now, regarding the most favored nations issue, I won't guess at what specifically the administration may choose to do. But speaking broadly, we acknowledge — I acknowledge, and I believe the industry acknowledges — that the gap in pricing between The United States and other countries for our innovative medicines has to be tackled. We're ready and willing to collaborate with the administration on that. And I believe it matters that I point to a few things we view as the key focus areas. Above all, we as an industry and Merck still hold the view that PBM reform would be one significant move. Consider the reality that more than $0.50 out of each dollar ends up somewhere in the middle, meaning the discoverers and manufacturers receive under half of each dollar. If we could figure out how to return more of that to the patient at the pharmacy counter, that could substantially lower prices in The US. That would be a significant move to make to narrow the differential. And second, I agree — I think you likely saw the recent remarks from some of my peers — but I agree that we must keep pressing foreign governments to grasp that they need to provide fair value for the innovation we deliver. And that they provide access to their patients, so we can bring the medicines to them. And it's at prices that reward us for the risk and innovation that we have. And I believe that's another key element. We devote time individually as a company and together with our other industry peers to advancing that argument wherever we can across the globe; and we will keep doing so. And then, as I noted, finally, we're very open to working with the administration to find solutions to address this. But what matters is we must ensure we safeguard access in The United States and we safeguard the innovation engine we have and the jobs it creates, and the strength of this industry as a key contributor to The United States. We don't want to lose the leadership we hold in this important field and that's what we're striving to advocate for as we work with the administration.

Peter Dannenbaum

executive
#15

Thanks, Vamil. Could we have the following question, please?

Chris Schott

analyst
#16

We'll now take a question from Chris Schott at JPMorgan. Please proceed. Your line is open. Thanks a lot. I only have one item, a brief follow-up to something asked before. Regarding that topic, could you share your views on GARDASIL and the possibility of switching to a single dose in The US? I'd like to hear what you think about the chances of a recommendation there and whether Merck could adjust its price if that happened. My follow-up concerned manufacturing and the longer-term tariff mitigation work. Should we expect that work to concentrate mainly on pipeline and new products, or could those longer-term efforts also cover legacy products like Keytruda? Thank you.

Dean Li

executive
#17

Yes, Chris. I appreciate the question. Let me take the Gardasil reduced dosing topic, and I believe you mean ACIP and the possible deliberations related to lower dosing. I don't want to guess what ACIP might do, but I do want to stress how extremely confident we are about Gardasil nine's safety and efficacy and about the dosing regimen. I'd also stress that the FDA has given us clear, firm, consistent, and recent guidance about what licensure of a single dose or reduced dosing would demand. They are very clear about the high evidentiary standard; they tell us it has to show efficacy against disease endpoints rather than only infections. You need data covering both males and females. Given that HPV-related head and neck cases in males are actually more numerous here in The United States than cervical cancer, they stressed to us a high statistical bar, and they also stressed long-term durability of protection. The FDA is remarkably current and mindful of what existing trials cannot show, and none of them satisfy the criteria needed for a label change. So a gap seems to exist between the rigorous clinical requirements the FDA has laid out and certain proposals now before the ACIP. What we hope for is a thorough discussion and questioning in a public forum about that obvious mismatch in the evidentiary standard—set by us, set for us by the FDA—and the choices ACIP is weighing. Caroline, would you like to take the other question?

Caroline Litchfield

executive
#18

Absolutely. As for whether the ACIP ought to consider some other dosing schedule, our position is firm regarding the benefit Gardasil delivers by stopping particular HPV-linked cancers. We will work to make sure that cost-effectiveness is recognized while we set the vaccine’s price appropriately. Rob, would you like to address the other question now — the one about manufacturing and the longer term? My apologies for that.

Rob Davis

executive
#19

Yes, I was really enjoying what you had to say. I lost track of the other question. My apologies for that. Chris, regarding what you asked about manufacturing, the answer is genuinely both. So obviously, we're putting a lot of emphasis on new products, and a few of those are already available in The United States. For others, we're going to be working to bring them into The United States. But we were also heavily focused on Keytruda. As you can probably figure out, Keytruda represents our largest exposure. That's true in the near term, but I feel quite confident that, as we sit here right now, with what I mentioned earlier — the fact that we essentially have inventory on hand in The United States that shields us through all of 2025; and then we've taken measures to be ready on both the drug substance side and the drug product side as we head into 2026 and 2027 — we're as well-positioned as anyone could be, thanks to both those short-term inventory moves and locking in additional manufacturing capacity in The United States. That includes contract manufacturers, and beyond that, we're already in the process of shifting toward our own internal manufacturing. So when it comes to KEYTRUDA, we're as well-positioned as it's possible to be. Naturally, we have to wait and see what the tariffs turn out to be, so I'd rather not address the specific implications, since that hinges on what form they take. But I believe we're well-positioned on both Keytruda and the new products.

Peter Dannenbaum

executive
#20

Thanks, Chris. Let's take the next question.

James Shin

analyst
#21

Our next question comes from James Shin at Deutsche Bank. Please go ahead. Your line is open. Good morning, and thanks for taking the question. The first one is for Rob. Rob, you've already shared a solid level of US investments. But do you need more, or is there room for additional US CapEx? And does that depend on US tax reform? Then a second one for Dean. With the recent PD-1 VEGF datasets, do you and your team now want to, or perhaps plan to, direct more resources toward the development of L M two nine nine? Thank you.

Rob Davis

executive
#22

Yeah, thanks for asking. So as things stand today, as we said, between the $12 billion we've completed plus the $9 billion plus that we have underway, we're going to be looking at north of $21 billion since 2018 across the coming few years. I really believe that over time, you're going to see that increase. As we keep going, because that reflects the firm decisions we've already made, so it doesn't include an expectation; those are actually firm decisions; and when we think about bringing manufacturing back, I think you will in fact see that number rise. The tax environment, clearly, we need to consider all of this holistically, but it will not change how we think about investment. We believe we can make the investments we need and handle our tax position very effectively at the same time.

Dean Li

executive
#23

Right. So, regarding that VEGF PD-1 question, I believe you mean what's come up with Harmony, those two and six readouts. Something that has been really steady — and I think this is what the field wants to know — is whether progress on PFS compared with a single PD-1 can carry over into OS, and whether work done only in China could be replicated on a global scale. That said, we welcome the strides being made in this area, and in our view KEYTRUDA has set the bar high, with 41 indications spanning 18 tumor types. As you're aware, we have our own PD-1 VEGF, and our decisions will be gated as our data and other data develop; yet as you note, we're firmly of the view that we hold the advantage, thanks to clinical expertise, the extensive data we've generated, and in a sense, having both a Keytruda and a Leap playbook at our disposal. Our intent would be to move quickly and with energy. Just as important, or perhaps most important, if that PD-1 VEGF were to demonstrate an OS benefit, we'd also benefit from having unique portfolio agents with obvious potential for combining. So as we make these decisions, we're watching both our own data and what's happening in the field.

Rob Davis

executive
#24

And perhaps I'd like to mention as well that, you know, if that bispecific pans out, you know, I believe it's reasonable to expect the effect on us will be — since this would probably arrive, honestly, most likely after Keytruda's LOE — fairly minor. When you consider non-small cell lung cancer, where a rival might potentially enter, at that point we'll be at just mid-teens. That's the maximum for our business. And keep in mind, we're working extremely hard, extremely diligently, to shift people toward the earlier stage setting; and when we accomplish that, they lack an indication there. So seen that way, our exposure is very limited. But what I truly want to stress is that the opportunity here is substantial; and I believe that's what Dean is getting at. Honestly, I think this might be a genuinely positive development for Merck over the long term.

Peter Dannenbaum

executive
#25

Excellent. Thank you, James. Let's take the following question.

Steve Scala

analyst
#26

We now have Steve Scala of TD Cowen on the line. Please proceed. Your line is open. Many thanks. About the worldwide deceleration in GARDASIL's expansion, which appears to be a fresh disclosure, what additional details came to light after Q1, when the business discussed growth in every single market? Does a clear path still exist toward $11 billion, a figure reiterated during the Q4 call? Also, does 02/2025 remain the bottoming-out year? Thanks.

Caroline Litchfield

executive
#27

Steve, thank you for asking. To begin with, the details we are offering concerning chances to expand Dartasil beyond China are not novel. What we are emphasizing instead is highly effective implementation by our Japanese colleagues of a catch-up cohort initiative concluding on March 31 of this year; because of that conclusion, we anticipate that in Japan alone we will mirror the primary age cohort and thus, starting in quarter two, drop back to what we delivered across earlier quarters. When examining Gardasil worldwide for this year, we anticipate China will act as a drag. Earlier we stated that with respect to China, we would evaluate whether or not to send additional products this year at the halfway point of this year? That evaluation will indeed happen at the halfway point of this year. Still, given today's conditions in China, expect that shipping additional products there is not very probable, and in fact that result is baked into the midpoint of our guidance. Having said all this, we do anticipate robust expansion outside China — robust double-digit, which we delivered in the first quarter — and we anticipate that robust expansion to continue throughout the rest of the year. Regarding longer-term guidance, we pulled the $11 billion objective last quarter, since China played a significant role in reaching that $11 billion. Our company stays committed and present on the ground in China to seize the greatest opportunity and maximize the launch among males, while we operate everywhere around the globe to safeguard far more lives from HPV-related cancers and generate growth for our business going forward.

Peter Dannenbaum

executive
#28

Great, thanks Steve. Can we take the next question now? Operator: Alex Hammond from Wolfe Research is up next. Go ahead, your line is open.

Alex Hammond

analyst
#29

Thanks for taking my question. At the ACIP meeting, you discussed the language around the HPV recommendation shifting from 11 to 12 years old eligible at nine, to a recommendation of two, nine to 12. A vote on that is expected at the June meeting. How significant do you view this language change in terms of its effect on US sales? And based on your doctor checks, do you see the broader recommendation becoming a meaningful tailwind? Thank you.

Rob Davis

executive
#30

Yeah, thanks for the question. When we consider the possible recommendation that might arrive in June, based on what you're saying, it looks like they may broaden it to cover ages nine and older. I actually see that as a significant and encouraging step forward. The reason is, first, when you think about teenagers getting vaccinated in their early teen years, if they end up requiring several doses, achieving completion of the entire vaccination series becomes more difficult. By beginning at age nine, there's a greater likelihood that individuals will finish the whole schedule, and that's a good thing. Also, when a child is nine, there typically aren't many other shots being given. That means families can really concentrate on getting the Gardasil dose during that period, which I think makes it simpler for them to make it a priority. So we consider that a good thing. I wouldn't call it a major boost for the US, though. We've generally seen this as a step-by-step change that matters. And really, even though this recommendation will carry weight, the age group already has approval right now. And as a matter of fact, you can already observe shots being administered. That guidance from ACIP really backs this up. All right, thank you, Alex. Let's take the following question.

Umer Raffat

analyst
#31

Our next caller is Umer Raffat with Evercore. Please proceed. Your line is live. Appreciate you allowing me to ask. If I could, there's one straightforward item I'd like to raise. Rob, do you plan to retain the intellectual property for KEYTRUDA sub q within the United States? Instead of Ireland, as we approach a possible approval? Thank you.

Rob Davis

executive
#32

Yes. In fact, I don't believe we have ever revealed the location of that IP for sub q, and I don't want to, you know, get into a conversation about it. So I think my preference would be not to address that, purely for reasons related to proprietary concerns.

Peter Dannenbaum

executive
#33

Thanks, Umer. Let's take the next question.

Akash Tewari

analyst
#34

Our next inquiry comes from Akash Tewari at Jefferies; so here are a few questions about tariffs that admittedly aren't fair. First, should we reasonably expect a 25% tariff? Or is it your view that the announced figure will be larger? How confident are you that, should they be announced, they will at least be implemented in a thoughtful way, whether through a gradual rollout or a faster regulatory pathway? To relocate manufacturing to The US quickly, and then lastly, suppose they ultimately land at 25%. With sensible mitigation steps, might the effect on Merck be somewhere in the single-digit range when it comes to earnings? As a percent? Thank you very much.

Rob Davis

executive
#35

Yes. Well, I'm grateful for that question. Look, I'd rather not guess about potential tariffs, since we must first learn what the administration actually says. What matters, I believe, is this: as I mentioned earlier, we've already acted — managing inventory for the near term and beginning to shift where we manufacture for the mid to long term — so I believe we're in a strong position across nearly all possible outcomes they might deliver. Still, regarding those particular details you're after, I won't engage in guesswork, because we have to wait and see what the actual measure turns out to be.

Peter Dannenbaum

executive
#36

Thank you, Akash. Let's take the next question.

Mohit Bansal

analyst
#37

Our next question comes from Mohit Bansal with Wells Fargo. Please go ahead. Your line is open. Hi, I really appreciate you taking my questions. I'd like to ask about the BD strategy. What we've noticed recently is that you've picked up quite a few assets out of China. I mean, I mean, I certainly get how cost-effective those are, but at the same time, they don't appear to be an innovative space. Correct? And as far as I can tell, I think you're the first mover in this area. The top two, give for an healthy little a and even the Jet PD one. So it's like, why doesn't this come across more like a company such as Merck is pursuing the front runners rather than attempting to be something, you know? Trying to do something innovative. We would really like to hear your thinking on that. Thank you.

Dean Li

executive
#38

Yeah. I'll be the one to answer that first. So to begin, I'd remind everyone that I would look at the Ocellarion purchase and winravir as delivering a front-leading molecule, and I would likewise look at the move to t o 1 A Into Lasoka Park as doing that too. And I'd restate how excited I am about our acquisition of iBio when it comes to wet AMD and diabetic macular edema. I should also stress that when you mention particular compounds, say, an LP little a or a GLP, I'd remind you as well that we hold we hold a goal of having the first and best oral PCSK nine. It will be first to market. We believe it will be the most effective. We have a lot of confidence in the cardiovascular outcomes; but we also have a lot of confidence in its capacity to combine with certain agents. So when you consider some of the BD, I might not view it separately from the remainder of the of the pipeline. I believe there are particular combinations that would be extraordinarily innovative that would need a combination, but a portion of the innovation at the base of that innovation originates from comes from our company, and it's a coordinated one pipeline, external, internal pipeline merging into a final prod. Rob, would you like to add anything?

Rob Davis

executive
#39

Right. Perhaps I should just add a few things to that. I believe we've struck a good balance. Dean provided several excellent illustrations of situations where we lead the field and, honestly, where nobody does it better. At the same time, we're examining additional approaches in which we may not be the leader, yet we still believe we can deliver best-in-class results. So the whole portfolio needs to be considered, rather than only the last 3 transactions we completed. And my honest expectation is that you'll keep seeing us pursue a variety of opportunities spanning the entire range. The reason is that, from our perspective, everything comes down to how we set ourselves up to grow. And for certain of these therapeutic areas, our view is that unmet need remains. Dean touched on this somewhat, but take obesity — a next wave could emerge there. Based on whatever happens with the p d one VEGF, that might become a next wave in which, honestly, pairing it with other agents in our lineup could let us take the lead too. So I don't consider that a fair way to describe it, and I'd encourage you to view things through the lens of the whole portfolio.

Peter Dannenbaum

executive
#40

Alright, thank you so much, Mohit. I believe we've gone beyond the hour at this point. So I really appreciate everyone spending your time and focus with us today; and should you have any further questions, please get in touch with IR. Thanks so much to all of you.

Operator

operator
#41

That concludes today's conference. Thank you for participating. You may disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.